DailyDoctor Archive Specialties Get app
Back to the 12 September 2026 edition

Clinical update · 02 of 06

CAR-T for general paediatricians: what happens after the centre discharges them

A child in remission after CAR-T is immunodeficient until proven otherwise — treat fever accordingly and keep immunoglobulin replacement under active review.

Chimeric antigen receptor T cell therapy has changed outcomes for children and young adults with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia, producing deep, often measurable-residual-disease-negative remissions even after failed chemotherapy or transplant. It is delivered only at designated centres under a strict clinical pathway. This review is aimed squarely at the paediatrician who will see the child afterwards.

The acute toxicities belong to the centre: cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. The longer-term problems come home. Prolonged cytopenias, sustained infection risk, B-cell aplasia and hypogammaglobulinaemia requiring immunoglobulin replacement are all consequences of the treatment working as designed — CD19 is on normal B cells as well as malignant ones.

Relapse also remains frequent, through loss of CAR-T persistence or antigen escape, which means a child in remission after CAR-T is under surveillance rather than cured. For a shared-care paediatrician the practical content is knowing that a febrile child with B-cell aplasia and hypogammaglobulinaemia is functionally immunodeficient regardless of how well they look, that immunoglobulin replacement is not optional, and that vaccine responses cannot be assumed.

  • Treat fever in a post-CAR-T child as fever in an immunodeficient child, whatever the blood count
  • Confirm immunoglobulin replacement is continuing and check trough levels
  • Do not assume vaccine responses; B-cell aplasia may persist for months or longer
  • Know the designated centre's contact route before you need it
  • Explain to families that remission after CAR-T means surveillance, not discharge

Why it matters

The toxicity that reaches the general paediatrician is not the dramatic one, and it lasts far longer.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

immunisationpaedemergencyadolescentgrowthneonatal

Tomorrow morning, before your first patient

One edition a day for paediatrics, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app